Promising drug combo targets Hard-to-Treat bone cancer
NCT ID NCT05830084
First seen Jan 08, 2026 · Last updated Jun 14, 2026 · Updated 21 times
Summary
This early-phase trial tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The study includes 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The main goal is to find the right dose and check for serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Bordeaux
Bordeaux, France
-
Centre Oscar Lambret
Lille, France
-
Gustave Roussy
Villejuif, Île-de-France Region, 94805, France
-
Institut Curie
Paris, France
-
Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Monash Children's Hospital
Clayton, Australia
-
Perth Children's Hospital
Perth, WA6009, Australia
-
Princess Máxima Center
Utrecht, 113, Netherlands
-
Queensland Children's Hospital
Brisbane, Australia
-
Rigshospitalet
Copenhagen, DK-2100, Denmark
-
Royal Children's Hospital
Parkville, Australia
-
Vall d'Hebron University Hospital
Barcelona, 119-12, Spain
-
centre Léon Bérard
Lyon, France
Conditions
Explore the condition pages connected to this study.